PIVOT PROTOCOLS
30-Day PCO Program · Version 3.1
Strategic Overview & Architecture
Confidential Working Document
Why PCO — Not Maintenance
This population doesn’t need a maintenance model. They need a bridge. Long-term medication management is clinically justified in full agonist OUD because the alternative — fentanyl, heroin, unmanaged street opioids — carries acute mortality risk. That risk profile doesn’t apply here. 7-OH and kratom extract users face a dependence that is kinetic in nature, driven by dosing frequency and receptor cycling, without the overdose mortality equation that warrants indefinite pharmaceutical enrollment.
What makes this population complex isn’t mortality risk — it’s nervous system sensitization. The short-cycle dosing pattern is neurologically aggressive, kindling the withdrawal response with each passing cycle and compressing the window between stability and crisis. Standard tapering doesn’t address this. It extends it.
The PCO overwrite targets both dimensions simultaneously. A long-acting partial agonist stops the sawtooth, interrupts the kindling cycle, and then — through its own pharmacokinetics — performs a passive, linear taper as it clears the system over 10–14 days. One intervention. Two problems. Clean exit.
The goal is not enrollment. It’s pharmacokinetic resolution followed by behavioral stabilization — and then out.
Program Resources
Stability Framework · Quit Plan Tool
What Pivot Is
Pivot Protocols is a referring agency and behavioral health education platform.
Pivot is not a medical or clinical entity:
Pivot does not prescribe, diagnose, or manage treatment
Pivot does not adjust medications or direct clinical care
Pivot does not intervene in the patient–physician relationship
Pivot provides:
Structured education
Referral pathways
Behavioral support frameworks
Decision-structure during destabilization and transition into care
All clinical decisions are made solely between the patient and their licensedmedical provider.
Stability Framework: pivotprotocols.com/stability-framework
Quit Plan Tool: pivotprotocols.com/home/build-your-quit-plan
The Problem Being Solved
Individuals dependent on kratom extracts and 7-hydroxymitragynine (7-OH) products face a structural gap:
No widely recognized clinical framework for short-cycle dependence
Limited provider familiarity with 7-OH pharmacology
Standard treatment models not designed for rapid-cycle withdrawal patterns
Harm reduction systems not built for this specific profile
The result: the 3 AM instability window — with no structured off-ramp.
The Core Insight
Buprenorphine/naloxone was originally developed and studied as a short-term detoxification agent in clinical settings. The long-term maintenance model emerged later.
Pivot's PCO model recovers the short-term stabilization use case — rather than introducing a novel treatment concept. This framing is grounded in existing clinical literature and historical use patterns. It does not introduce a new treatment — it structures the behavioral and educational environment around an existing clinical option.
The Program Model
Phase One — The PCO Month (Pivot's Operational Lane)
The PCO Month is a structured education and behavioral containment program that runs alongside, but separate from, clinical care.
It focuses on:
Behavioral stabilization
Decision-structure
Expectation management
It does not include:
Medical stabilization
Medication management
Pre-Entry
Quit Plan Tool intake — pivotprotocols.com/home/build-your-quit-plan
Volatility Density Index (VDI) baseline
Delivery of PCO educational document
Curated list of independent telehealth prescribers familiar with this general clinical territory
Patient independently schedules appointment and, if appropriate, returns with medications prescribed by their clinician
Pivot:
Does not schedule or attend clinical visits
Does not influence prescribing decisions
Does not receive compensation from prescribers
Does not guarantee any clinical outcome
Clinical Conversation Categories (Patient–Provider Discussion)
Pivot does not recommend or direct specific medications. Patients are educated on categories commonly discussed with providers, enabling more structured and informed conversations:
Opioid stabilization approaches
Often involving partial agonists or other medications, as determined by the clinician.
Non-addictive anxiety support
e.g., non-controlled or other clinician-selected anxiolytics, if appropriate.
Autonomic regulation supporte.g., agents addressing sympathetic activation, selected solely by the clinician.
Sleep continuity support
e.g., non-controlled or provider-approved sleep aids, if used — availability varies by platform; local prescribers may offer broader options.
Examples of medications may be referenced strictly for terminology recognition — not as recommendations. All selection, dosing, timing, and prescribing decisions are made exclusively by the treating clinician.
These categories are designed to help patients enter clinical conversations with clarity and structure, not to replace or guide medical decision-making.
Weeks 1–4: Structured Stabilization & Containment
Weeks 1–4 focus on behavioral stabilization and containment during the transition into care:
Weekly VDI check-in — tracking volatility trajectory against baseline (Stability Framework)
Weekly group call — founder-led initially, contractor-led at scale
Behavioral guidance using the Stability Framework
PCO document as the educational backbone throughout
Containment refers to:
Structure
Expectation alignment
Decision stability
Not:
Clinical control
Medication direction
Critical Retention Architecture
Pre-Framing (Pre-Entry + Week 1)
"Early relief is stabilization — not completion."This framing is introduced at intake and reinforced throughout Week 1 to set accurate expectations before the inflection point arrives.
Week 2 Inflection Point — Required Intervention
Dedicated session addressing premature exit risk
Normalization of the "I feel better → I'm done" pattern
Re-anchoring to completion and system stabilization
This is a designed behavioral containment point — not optional. It targets a known dropout pattern without interacting with medication schedules or clinical decisions.
Phase Two — If Stabilization Does Not Hold
Phase Two is informational only.
If stabilization does not hold — or if the treating clinician determines that a different approach is appropriate — Pivot provides:
A written educational document describing longer-acting treatment categories present in clinical practice, including extended-release medication approaches (e.g., long-acting injectable formulations used in buprenorphine-based treatment)
Guidance on how to locate appropriate prescribers
Navigation support for insurance considerations
Instruction on how to structure productive provider conversations
This content:
Describes what exists in the treatment landscape
Helps patients understand terminology and pathways
Does not recommend any specific product, dose, schedule, or regimen
Pivot does not coordinate, participate in, or manage ongoing treatment in Phase Two. Pivot provides a structured map of next-step options and exits the process.
Program Fees & Scope of Service.
Pivot Protocols charges a fee for:
Educational materials
Behavioral guidance
Structured group sessions
Access to the program framework and tools
The fee does not cover:
Medical care
Prescriptions
Clinical services
Outcomes or results
Payment is for participation in a structured educational and behavioral support program only.
Participation does not establish a provider–patient relationship with Pivot Protocols.
All medical services are:
Independent
Arranged directly between patient and provider
Billed separately by those providers
Liability Framework
Low-Risk Elements
Referring agency model is well established in behavioral health and education contexts
Educational publishing is protected when clearly non-directive
No prescribing, diagnosis, or clinical management at any point
Managed Gray Zones
Patient-facing materials must educate on history and categories — not script the clinical conversation. Population vulnerability requires clear and repeated non-clinical role boundaries
Language must consistently reinforce non-clinical positioning and deference to licensed providers
Core Boundary Statement (Non-Negotiable)
Pivot Protocols does not recommend, direct, or instruct any specific medication, dose, or treatment plan. All clinical decisions are made solely between the patient and their licensed medical provider.
This statement must appear in: program materials, PCO document, terms of service, and key site pages.
Mitigation
Risk level: manageable — not zero. Healthcare attorney review of terms of service and PCO document prior to launch
Estimated cost: $500–$1,500
Why This Model Can Work
Underserved market — No structured off-ramp currently exists for this population
Aligned positioning — Education, referral, and behavioral containment — not treatment provision
Clinically grounded framing — Anchored in historical use of existing medications for short-term stabilization
Economic viability — Target users already sustaining high spend in the retail pharmacology ecosystem
Proof of concept — Founder-led experiential validation and real-world pattern recognition across 23 years of front line recovery leadership
Primary Viability Risk — Early Stabilization Dropout Pattern:
Rapid improvement → perceived completion → premature exit
Behavioral solution:
Pre-framing at intake: relief signals stabilization, not completion
Designed Week 2 intervention targeting the known dropout inflection point
Structured containment messaging throughout the full PCO Month
Build Sequence
PCO educational document — original indication framing, provider conversation categories, boundary language throughout
Curated prescriber list — observational notes on general tendencies; exploratory outreach to identify prescribers open to short-term detox framing and broader supportive medication options
Program overview + sales page — positioning Pivot as the routing and stabilization layer
Week 1 guidance content — stabilization framing, early expectations, retention pre-framing
Week 2 retention module — non-optional behavioral containment session targeting premature exit
Scaling Path
Now — Manual Delivery
Quit Plan Tool as intake
Founder-led group calls and guidance sessions
Manual delivery of PCO document and prescriber list
Next — MVP with Kevin
VDI dashboard with weekly self-reporting
Automated check-in cadence
Group call scheduling and replay library
Independent contractor on-boarding system
Integrated prescriber directory built into the platform
Long-Term — BCaaS Infrastructure
Behavioral Containment as a Service — platform-level infrastructure
Acquisition potential across: telehealth, pharmaceutical, recovery organizations, retail pharmacology ecosystem
Current use case as the most complex proof of concept for the broader BCaaS model
System Definition
Pivot is not a treatment provider. It is a routing and stabilization layer between instability and clinical care.
Translates a misunderstood dependence pattern into language clinicians can work with
Structures the entry into care for a population that currently has no map
Stabilizes behavior during the transition window
Exits before long-term clinical entanglement or medication management
Summary
Legally bounded · Operationally executable · Market-aligned Scalable as infrastructure
Pressure Test Lens
Does this feel useful without being directive?
Does it provide decision-structure without prescribing behavior?
Does it maintain authority without crossing into treatment?
Does it give enough clarity to act without overstepping clinical boundaries?
Strategic Note
This version resolves the core tension — it no longer feels like it's holding back. It feels like it's structuring access. That's exactly where it needs to be.